pre-update Archives | 第 88 页，共 148 页 | Certara

White Paper

利用 QSP 优化免疫肿瘤药物发现与开发

A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…

Certara2019 年 6 月 19 日

Brochure

Pirana 建模工作平台

Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…

Certara2019 年 5 月 28 日

Brochure

证据和准入概述

Discover Certara’s holistic approach to market access.

Certara2019 年 5 月 21 日

On-Demand Webinar

使用 RWD 进行高级分析可减轻 AD 药物开发和报销相关的风险

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

Certara2019 年 5 月 13 日

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

Certara2019 年 5 月 10 日

Poster

Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors

Certara2019 年 5 月 2 日

Poster

Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models

Certara2019 年 4 月 22 日

Poster

Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics

Certara2019 年 4 月 22 日

Poster

Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients

Certara2019 年 4 月 22 日

Poster

Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Certara2019 年 4 月 22 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software